A regimen containing rifabutin for the treatment of tuberculosis in patients intolerant to rifampin [4]

Clinical Infectious Diseases

Volumn 36, Issue 1, 2003, Pages 127-128

  Tattevin, Pierre ^a   Revest, Mathieu ^a   Dupont, Mathieu ^a   Arvieux, Cédric ^a   Michelet, Christian ^a  

^a PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN;

ADULT; AGED; DRUG TOLERANCE; FEMALE; FLU LIKE SYNDROME; HUMAN; INFECTION RISK; LETTER; LUNG TUBERCULOSIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PRURITUS; RASH; RECURRENCE RISK; THROMBOCYTOPENIA; TUBERCULOSIS;

EID: 0037232687     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/345532     Document Type: Letter

References (5)

1. Small PM, Fujiwara PI. Management of tuberculosis in the United States. N Engl J Med 2001; 345:189-200.
2. Schluger NW. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients. Clin Infect Dis 1999; 28:130-5.
3. Brogden RN, Fitton A. Rifabutin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy. Drugs 1994; 47:983-1009.
4. Grassi C, Peona V. Use of rifabutin in the treatment of pulmonary tuberculosis. Clin Infect Dis 1996; 22:S50-4.
5. De Cian W, Sassella D, Wynne BA. Clinical experience with rifabutin in the treatment of mycobacterial infections. Scand J Infect Dis Suppl 1995; 98:22-6.